Antag Therapeutics is developing first‑in‑class GIP receptor antagonist peptides, such as AT‑7687, to treat obesity, type 2 diabetes, and related metabolic disorders. By blocking the GIP pathway that drives fat storage and insulin resistance, their approach aims to achieve meaningful weight loss and metabolic improvement while preserving lean mass and maintaining tolerability. The lead candidate is in Phase 1a trials as both a monotherapy and in combination with other obesity therapies.
Funding
$84.1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
5OFounders
Product
Problem
Obesity and related metabolic disorders affect millions worldwide, yet existing pharmacotherapies often cause gastrointestinal side effects, loss of lean mass, and insufficient weight‑loss outcomes, leaving many patients without effective, tolerable treatment options.
Solution
Antag Therapeutics is developing a novel class of obesity medicines based on glucagon‑like peptide‑1 (GIP) receptor antagonism. By blocking the GIP receptor, the approach aims to interrupt a dysfunctional pathway that promotes fat storage and insulin resistance, rather than stimulating incretin hormones. The lead candidate, AT‑7687, is a first‑in‑class peptide antagonist currently in Phase 1a trials, evaluated as both monotherapy and in combination with other obesity agents. This mechanism is intended to deliver meaningful weight loss and metabolic improvements while maintaining tolerability and preserving lean body mass, offering a more adaptable and personalized treatment paradigm for patients with obesity and type 2 diabetes.
Target Audience
Primary customers are pharmaceutical developers, clinical researchers, and healthcare providers seeking innovative, well‑tolerated therapies for patients with obesity, type 2 diabetes, and related metabolic conditions.
Features
- First clinical‑stage GIP receptor antagonist peptide targeting a novel mechanism of action
- Designed to reduce fat accumulation and improve insulin sensitivity without stimulating appetite pathways
- Evaluated as monotherapy and in combination regimens to enhance efficacy and flexibility
- Phase 1a double‑blind, placebo‑controlled trial assessing safety, tolerability, pharmacokinetics, and metabolic effects in both lean and obese subjects
- Emphasis on long‑term sustained health outcomes with a focus on tolerability and preservation of lean mass